Ocera Therapeutics

Ocera’s lead drug candidate OCR-002 is a novel ammonia scavenger which rapidly removes ammonia from the blood. Elevated ammonia is believed to be one of the primary causes of hepatic encephalopathy (HE). OCR-002 is the subject of STOP-HE, a Company-sponsored Phase 2b trial, and two investigator-sponsored Phase 2a trials. OCR-002 has received Orphan Drug designation in both the U.S. and Europe and has been granted Fast Track status by the U.S. Food and Drug Administration.

Company Growth (employees)
Type
Public
HQ
Palo Alto, US
Founded
2005
Size (employees)
20 (est)
Ocera Therapeutics was founded in 2005 and is headquartered in Palo Alto, US

Ocera Therapeutics Office Locations

Ocera Therapeutics has offices in Palo Alto and Durham
Palo Alto, US (HQ)
610 525 University Ave
Durham, US
300 5001 S Miami Blvd

Ocera Therapeutics Data and Metrics

Ocera Therapeutics Financial Metrics

USD

Market capitalization (27-Jun-2017)

30.5 m

Closing share price (27-Jun-2017)

1.1

Cash (31-Dec-2016)

24.6 m
Ocera Therapeutics's current market capitalization is $30.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

15.5 m10.1 m35.9 m24.6 m

Accounts Receivable

93 k62 k59 k

Inventories

470 k970 k627 k584 k

Current Assets

49.3 m48.3 m44 m28.9 m

PP&E

59 k61 k94 k64 k

Goodwill

595 k595 k595 k595 k

Total Assets

51.8 m53.1 m44.7 m29.6 m

Accounts Payable

1.3 m941 k701 k1.2 m

Total Debt

19 m

Current Liabilities

6.7 m2.9 m3.8 m13.8 m

Additional Paid-in Capital

126.6 m155.1 m162.8 m174.1 m

Retained Earnings

(104.9 m)(131.4 m)(158.3 m)

Total Equity

31.4 m15.7 m

Debt to Equity Ratio

0.6 x

Debt to Assets Ratio

0.4 x

Financial Leverage

1.4 x1.9 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(17.5 m)(23.4 m)(26.5 m)(26.9 m)

Depreciation and Amortization

295 k164 k171 k

Accounts Receivable

45 k31 k3 k

Accounts Payable

14 k(341 k)(240 k)514 k

Cash From Operating Activities

(12 m)(20.3 m)(20.6 m)(22.1 m)

Purchases of PP&E

(12 k)(38 k)(75 k)(14 k)

Cash From Investing Activities

(21.3 m)(8.9 m)33.2 m3.6 m

Cash From Financing Activities

7.2 m

Interest Paid

828 k
Y, 2016

Financial Leverage

1.9 x

Ocera Therapeutics Market Value History

Ocera Therapeutics Online and Social Media Presence

Ocera Therapeutics Company Life and Culture

You may also be interested in